No 'Unicorn' High-Cost/High-Volume Drugs Expected For 2017
Executive Summary
Specialty drugs, which have been a key driver of health care spending growth in years past, are not expected to have the same impact in 2017 – mostly because there's no "unicorn" high-cost, high-volume blockbusters, like the hepatitis C virus medicines Sovaldi and Harvoni, marketed by Gilead Sciences Inc., and Viekira Pak, sold by AbbVie Inc., anticipated to enter the market next year.